EP Patent

EP4124658A2 — Treatment of amyotrophic lateral sclerosis (als)

Assigned to Voyager Therapeutics Inc · Expires 2023-02-01 · 3y expired

What this patent protects

The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).

USPTO Abstract

The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).

Drugs covered by this patent

Patent Metadata

Patent number
EP4124658A2
Jurisdiction
EP
Classification
—
Expires
2023-02-01
Drug substance claim
No
Drug product claim
No
Assignee
Voyager Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.